Angiex initiates first-in-human trial of AGX101, a novel ADC targeting TM4SF1 to disrupt tumor blood supply

BiotechClient newsCase studyMedia relations

Dec 10

Written By Tim Cox

With the potential to revolutionize cancer treatment, Angiex's co-founder and CEO, Dr. Paul Jaminet, knew that effectively communicating its scientific advancements was crucial for securing funding, attracting investors, and ultimately, bringing its life-saving therapy to patients. Recognizing this challenge, Dr. Jaminet partnered with ZingPR to embark on a strategic PR campaign designed to generate excitement and build momentum for Angiex's innovative approach.

The Angiex story: a mission to cure cancer

Founded in 2015 by leading scientists in the field of angiogenesis, Angiex is on a mission to cure cancer by obliterating tumor blood vessels. The company's groundbreaking approach is based on the discovery that tumor vessels are fundamentally different from the vessels in the rest of the body, making them susceptible to targeted therapies.

Led by CEO and former astrophysicist Paul Jaminet, Angiex has spent years developing its lead candidate, AGX101, a safe and effective drug that has the potential to shrink tumors to microscopic size by eliminating their blood supply.

The challenge

Angiex was at a pivotal juncture, having just initiated its first-in-human Phase 1 clinical trial for its lead candidate, AGX101. This was a crucial milestone, marking the transition from preclinical research to human testing and signifying a major step towards potentially bringing this promising therapy to patients. However, with limited resources and a complex scientific story to tell, Angiex needed a PR strategy that would effectively communicate the significance of this milestone and attract the attention of key stakeholders.

The approach

The PR campaign focused on several key elements:

Highlighting the first-in-human milestone: the campaign emphasized the significance of the Phase 1 trial initiation, showcasing Angiex's progress and dedication to advancing cancer treatment.
Showcasing novel mechanisms of action: AGX101's unique approach to attacking cancer was a central theme. The campaign highlighted its dual mechanism of action, disrupting tumor blood vessels (angiogenesis) while delivering a potent cytotoxic payload directly to the nucleus of tumor cells.
Emphasizing the TM4SF1 target: the campaign explained the importance of targeting TM4SF1, a protein crucial for tumor growth and metastasis, and how this differentiated AGX101 from other ADCs.
Building thought leadership: Angiex's CEO, Dr. Paul Jaminet, played a key role in establishing the company's credibility and expertise. One useful outcome of the media outreach were several invitations to contribute thought-leadership articles to prominent publications like Labiotech and DDW — providing Dr Jaminet with platforms to highlight the challenges and opportunities in biotech innovation and cancer drug development.
Targeted media outreach: the campaign focused on securing coverage in top-tier biotech and science publications, including Labiotech, DDW, ADC Review, Biospace, Drug Discovery World, Clinical Trials Arena, Bio-IT World, PHARMABIZ, Contract Pharma, and Biopharma Reporter. Pitches were tailored to each outlet's specific interests and audience, ensuring maximum impact and reach.

Campaign results

The PR campaign generated significant results for Angiex:

Broad media coverage: ZingPR secured impressive coverage across a range of strategically important publications — reaching a diverse audience of investors, scientists, healthcare professionals, and the general public. This media exposure helped raise awareness of Angiex's innovative approach and the potential of AGX101 to transform cancer treatment.
Enhanced credibility: by highlighting the company's scientific rigor, the Phase 1 trial initiation, and Dr. Jaminet's thought leadership, the campaign solidified Angiex's position as a credible and promising player in the biotech industry.

Key takeaways

The PR campaign that ZingPR orchestrated for Angiex demonstrates the power of strategic communications to effectively announce critical milestones and generate buzz for biotech companies. By focusing on clear messaging, targeted outreach, and compelling storytelling, ZingPR helped Angiex communicate the significance of its first-in-human trial, attract investor attention to its novel ADC, and build momentum for its mission to revolutionize cancer treatment.

Watch this space!

Need help launching communicating your amazing biotech science? Click here to set up a call with me, Tim Cox.

Angiex

Tim Cox https://zingpr.com

Angiex initiates first-in-human trial of AGX101, a novel ADC targeting TM4SF1 to disrupt tumor blood supply

Angiex selected ZingPR to generate excitement and build momentum for the Phase 1 clinical trial of AGX101, a novel antibody-drug conjugate (ADC) designed to revolutionize cancer treatment by targeting tumor blood vessels. The campaign played a crucial role in communicating the potential of AGX101 to transform cancer treatment and attracting support for Angiex's mission.

Expanded Access Programs for ALS: how WideTrial took flight

WideTrial, a startup focused on expanded access programs (EAPs), partnered with ZingPR to announce its role in a major NIH-funded EAP for ALS. The challenge was to generate excitement while establishing credibility and navigating the constraints faced by many startups. How ZingPR helped WideTrial achieve significant media coverage in prominent publications.

The aging debate: why it matters (and how we made it matter more)

Recently, I had the chance to work on a fascinating project: promoting a debate on aging. Not your typical PR gig, right? But that's what I love about this field—the chance to work with innovative companies tackling big challenges. My goal was simple: make this debate unmissable. And more importantly, make it matter. Because the science behind it really matters.

Case study: transforming the narrative on PVC production

ZingPR helped Transform Materials, a Florida-based deeptech startup, announce a groundbreaking collaboration with Johnson Matthey that's set to revolutionize the PVC industry. Our strategic media outreach focused on highlighting the partnership's environmental benefits, scalability, and industry-leading expertise.